Lv2
190 积分 2025-01-25 加入
Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system
3个月前
已完结
Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting
5个月前
已完结
A real-world pharmacovigilance study of blinatumomab based on the FDA adverse event reporting system
6个月前
已完结
Disseminated intravascular coagulation is an underestimated but fatal adverse event associated with blinatumomab therapy: A pharmacovigilance analysis of FAERS
7个月前
已完结
Causal relationships between inflammatory factors and multiple myeloma: A bidirectional Mendelian randomization study
8个月前
已完结
皖公网安备34019202002308
